CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Trial of Trastuzumab (Herceptin; NSC #688097, IND #6667) in Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00004856
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:30.899950+00:00
Published At: 2013-05-03T00:00:00+00:00
Record Updated At: 2013-05-03
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Distal Urethral Cancer", "Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter", "Proximal Urethral Cancer", "Recurrent Bladder Cancer", "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter", "Recurrent Urethral Cancer", "Stage IV Bladder Cancer", "Transitional Cell Carcinoma of the Bladder", "Urethral Cancer Associated With Invasive Bladder Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2013-05-03"
protocolSection.identificationModule.nctId: "NCT00004856"
protocolSection.identificationModule.officialTitle: "A Phase II Trial of Trastuzumab (Herceptin; NSC #688097, IND #6667) in Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.